We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Role of benzydamine hydrochloride in the prevention of oral mucositis in head and neck cancer patients treated with radiotherapy (>50 Gy) with or without chemotherapy.
- Authors
Rastogi, Madhup; Khurana, Rohini; Revannasiddaiah, Swaroop; Jaiswal, Isha; Nanda, Sambit; Gupta, Pooja; Chufal, Kundan; Bhatt, M; Nanda, Sambit S; Chufal, Kundan S; Bhatt, M L
- Abstract
<bold>Purpose: </bold>Benzydamine is recommended for prophylaxis of oral mucositis (OM) in head and neck cancer (HNC) patients for radiation doses (<50 Gy). This study evaluates role of benzydamine for higher radiation doses (>50 Gy) with or without chemotherapy.<bold>Methods: </bold>One hundred twenty patients of HNC with planned radiation doses of ≥60 Gy were randomized to group A (control radiotherapy alone), group B (study radiotherapy alone), group C (control chemoradiotherapy), or to group D (study chemoradiotherapy). Groups A and C were advised saline mouth rinses, and in groups B and D, additional benzydamine rinses (0.15%) were advised. Mucositis grading was done with both WHO (WHO-M) and CTCAE (CTC-M) version 4.0 (common terminology criteria for adverse events) weekly.<bold>Results: </bold>Patient characteristics are presented in the table. Patients in group B had lesser grade 3 WHO-M and CTC-M as compared to group A, 62.1 vs. 36.4% (p = 0.038) and 51.7 vs. 27.3% (p = 0.043), respectively. The rates of Ryle's tube feeding (RTF), intravenous fluid supplementation (IVF), and hospitalization were also lesser in group B as compared to A, 34.5 vs. 21.2% (p = 0.18), 27.6 vs. 9.1% (p = 0.06), and 6.9 vs. 0% (p = 0.21), respectively. WHO-M and CTC-M in groups C and D were not statistically different, 64.3 vs. 43.3% (p = 0.091) and 53.6% vs. 43.3% (p = 0.30), respectively. The rates of RTF, IVF, and hospitalization were all lesser but p > 0.05.<bold>Conclusion: </bold>Benzydamine significantly reduces OM even at doses >50 Gy in HNC patients. Its role in patients receiving concurrent chemotherapy further needs to be evaluated.
- Subjects
ORAL mucosa; HEAD &; neck cancer patients; RADIOTHERAPY; CANCER chemotherapy; MEDICAL care
- Publication
Supportive Care in Cancer, 2017, Vol 25, Issue 5, p1439
- ISSN
0941-4355
- Publication type
journal article
- DOI
10.1007/s00520-016-3548-9